Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Tapping into the human microbiome yields MRSA-active antibiotics

Researchers develop new bioinformatics-based approach to natural product discovery

by Ryan Cross
October 24, 2016 | A version of this story appeared in Volume 94, Issue 42

Microbes are full of undiscovered molecules, including antibiotics. But many species remain difficult to culture or simply contain large swaths of genes that remain inactive under laboratory conditions. Hoping to harvest untapped molecules without growing a single cell, Sean F. Brady of Rockefeller University and colleagues looked to genomic data from the human microbiome for inspiration. “Genomic sequences are coming at us fast, and we need tools to turn that information into molecules,” Brady says. So the researchers mined previously reported DNA sequences for nonribosomal peptide gene clusters. With those data, they synthesized the predicted structures of 25 peptides and tested them for antibiotic activity. Two peptides, dubbed humimycin A and humimycin B, are effective against several pathogenic bacteria. Humimycin A drastically improved survival in mice infected with methicillin-resistant Staphylococcus aureus (MRSA) when given in conjunction with the antibiotic dicloxacillin (Nat. Chem. Biol. 2016, DOI: 10.1038/nchembio.2207). “This was just the first step of building complex molecules guided by bioinformatics,” Brady says. Next, his group plans to explore beyond the human microbiome to other microorganism habitats.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.